Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
11.86
-0.06 (-0.50%)
Aug 5, 2026, 3:10 PM EDT - Market open
Replimune Group Market Cap
Replimune Group has a market cap or net worth of $995.82 million as of August 5, 2026. Its market cap has increased by 126.22% in one year.
Market Cap
995.82M
Enterprise Value
843.55M
1-Year Change
126.22%
Ranking
Category
Stock Price
$11.86
ChartMarket Cap Chart
Since July 20, 2018, Replimune Group's market cap has increased from $467.50M to $995.82M, an increase of 113.01%. That is a compound annual growth rate of 9.85%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 5, 2026 | 995.82M | 30.60% |
| Dec 31, 2025 | 762.50M | -7.97% |
| Dec 31, 2024 | 828.50M | 66.40% |
| Dec 29, 2023 | 497.90M | -63.20% |
| Dec 30, 2022 | 1.35B | 6.46% |
| Dec 31, 2021 | 1.27B | -27.53% |
| Dec 31, 2020 | 1.75B | 281.78% |
| Dec 31, 2019 | 459.30M | 45.58% |
| Dec 31, 2018 | 315.50M | -32.51% |
| Jul 20, 2018 | 467.50M | - |
View and export this data all the way back to 2018. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Alpha Tau Medical | 1.08B |
| Alto Neuroscience | 1.06B |
| EyePoint | 1.04B |
| Lexicon Pharmaceuticals | 1.03B |
| Inventiva | 1.03B |
| Cullinan Therapeutics | 998.69M |
| Olema Pharmaceuticals | 985.28M |
| Avalo Therapeutics | 954.90M |